TABLE 2.
Tumor Histology and Management of Therapeutic Procedures by Surgery Year
| Overall (n = 467) | NSM before 2011 (n = 110) | NSM after 2011 (n = 357) | p-value | |
|---|---|---|---|---|
| Tumor Histology | < .001a | |||
| Invasive Cancer | 337 (72.2%) | 64 (58.2%) | 273 (76.5%) | |
| DCIS | 126 (27.0%) | 44 (40.0%) | 82 (23.0%) | |
| Phyllodes | 4 (0.9%) | 2 (1.8%) | 2 (0.6%) | |
| Invasive Tumor Subtype (n = 337) | 0.08 | |||
| HR+/HER2− | 232 (68.8%) | 42 (65.6%) | 190 (69.6%) | |
| HR+/HER2+ | 38 (11.3%) | 4 (6.2%) | 34 (12.5%) | |
| HR−/HER2− | 35 (10.4%) | 12 (18.8%) | 23 (8.4%) | |
| HR−/HER2+ | 17 (5.0%) | 3 (4.7%) | 14 (5.1%) | |
| Unknown | 15 (4.5%) | 3 (4.7%) | 12 (4.4%) | |
| Median Tumor Size (cm, range) | 1.2 (0–9) | 1.2 (0.1–8.2) | 1.2 (0–9) | 0.65 |
| T Category | 0.009b | |||
| Tis | 126 (27.0%) | 44 (40.0%) | 82 (23.0%) | |
| T1 | 268 (57.4%) | 52 (47.3%) | 216 (60.5%) | |
| T2 | 57 (12.2%) | 10 (9.1%) | 47 (13.2%) | |
| T3 | 2 (0.4%) | - | 2 (0.6%) | |
| Unknown/Others | 14 (3.0%) | 4 (3.6%) | 10 (2.8%) | |
| Nodal Status | 1.0 | |||
| Node Negative | 390 (83.5%) | 92 (83.6%) | 298 (83.5%) | |
| Node Positive | 77 (16.5%) | 18 (16.4%) | 59 (16.5%) | |
| Breast Cancer Stage | 0.005c | |||
| 0 | 123 (26.3%) | 43 (39.1%) | 80 (22.4%) | |
| I | 230 (49.3%) | 42 (38.2%) | 188 (52.7%) | |
| II | 83 (17.8%) | 16 (14.5%) | 67 (18.8%) | |
| III | 18 (3.9%) | 4 (3.6%) | 14 (3.9%) | |
| Unknown | 13 (2.8%) | 5 (4.5%) | 8 (2.2%) | |
| Axillary Procedure | < .001d | |||
| SLNB | 388 (83.1%) | 75 (68.2%) | 313 (87.7%) | |
| ALND | 54 (11.6%) | 21 (19.1%) | 33 (9.2%) | |
| None | 25 (5.4%) | 14 (12.7%) | 11 (3.1%) | |
| Neoadjuvant Chemotherapy (n = 449) | 0.14 | |||
| Yes | 33 (7.3%) | 4 (3.8%) | 29 (8.4%) | |
| No | 416 (92.7%) | 101 (96.2%) | 315 (91.6%) | |
| Adjuvant Chemotherapy (n = 449) | 0.72 | |||
| Yes | 150 (33.4%) | 37 (35.2%) | 113 (32.8%) | |
| No | 295 (65.7%) | 68 (64.8%) | 227 (66%) | |
| Unknown | 4 (0.9%) | 0 (0%) | 4 (1.2%) | |
| PMRT (n = 467) | 0.55 | |||
| Yes | 37 (7.9%) | 7 (6.4%) | 30 (8.4%) | |
| No | 428 (91.6%) | 103 (93.6%) | 325 (91.0%) | |
| Unknown | 2 (0.4%) | - | 2 (0.6%) | |
| Adjuvant Endocrine Therapy (n=449) | 0.001e | |||
| Yes | 233 (51.9%) | 40 (38.1%) | 193 (56.1%) | |
| No | 210 (46.8%) | 65 (61.9%) | 145 (42.2%) | |
| Unknown | 6 (1.3%) | 0 (0%) | 6 (1.7%) |
NSM nipple-sparing mastectomy, DCIS ductal carcinoma in situ, SLNB sentinel lymph node biopsy, ALND axillary lymph node dissection, PMRT postmastectomy radiation therapy
a
bold denotes there was a significant increase in the number of therapeutic NSMs performed for invasive tumor histology after 2011
b
bold denotes patients after 2011 tended to have a higher T stage
c
bold denotes patients after 2011 tended to have a higher overall TNM stage
d
bold denotes patients after 2011more frequently received SLNB
e
bold denotes patients after 2011 more frequently received adjuvant endocrine therapy